Introduction {#s1}
============

Aurora kinase A (AURKA) is a cell-cycle regulatory serine/threonine kinase that promotes cell cycle progression ([@B1]). AURKA is expressed in proliferating cells, especially in the G2 and mitotic phases of the cell cycle. It has various roles in promoting cell division, including the establishment of the mitotic spindle and centrosome separation ([@B1]). The AURKA gene is located at chromosomal locus 20q13.2 according to the HUGO Gene Nomenclature Committee (HGNC), and is often amplified in cancers ([@B2]--[@B4]). AURKA amplification has been found in certain tumor types, including colorectal, leukemia, and pancreatic cancers ([@B3], [@B5], [@B6]). Overexpression of AURKA can promote cellular transformation and may potentiate the activity of other oncogenes, such as RAS, further promoting tumorigenesis ([@B7]).

AURKA rs2273535 T\>A, also known as F31I or Phe31Ile, is caused by a T-to-A transversion at position 91 in the AURKA coding sequence. This single nucleotide polymorphism is located in the Aurora Box1 (aa 5-40) motif, which belongs to the NH2-terminal region of aurora-A. This motif is thought to act on ubiquitin-based proteolysis ([@B8]).

Up until now, there have been many studies that have investigated the association between the AURKA F31I polymorphism and the risk of different types of cancer in different populations. However, the results are inconsistent, most likely because the sample size is relatively small in each published study, and the impact of the polymorphism on cancer risk might be small. Therefore, we conducted a comprehensive meta-analysis by identifying as many relevant articles as possible to identify evidence for the link between the AURKA F31I polymorphism and cancer risk.

Materials and Methods {#s2}
=====================

Search Strategy
---------------

Two authors (JQ and SW) conducted the search for relevant articles before December 2018, using the following terms, "AURKA or Aurora Kinase A," "tumor or cancer or carcinoma or neoplasm," and "polymorphism or single-nucleotide polymorphism (SNP) or variant," in the PubMed, EMBASE, CNKI, WANFANG, and Vip databases. We also examined the references of the retrieved publications for additional eligible studies.

Eligibility Criteria
--------------------

Publications retrieved from the various databases were assessed for eligibility according to the following criteria: (1) the publication was published in English or Chinese; (2) the publication evaluated the association between the AURKA gene rs2273535 polymorphism and cancer risk; (3) the publication was a case-control study; the publication with the largest number of individuals was selected if studies had duplicate subjects. In addition, publications were excluded according to the following criteria: (1) genotype data included were not sufficient to calculate an odds ratio (OR) and 95% confidence interval (CI); (2) only survival data was included; (3) the genotype frequency distribution departed from Hardy-Weinberg equilibrium (HWE) in the controls.

Data Extraction
---------------

The following information was independently extracted by two authors (SW and JQ): first author name, year of publication, cancer type, region, ethnicity, genotyping method, source of controls (hospital-based, population-based, and mixed), the genotype counts of cases, and controls for the investigated polymorphism.

Quality Assessment
------------------

Two authors (SW and JQ) independently assessed the quality of the included studies according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) quality scoring system ([@B9]). Forty evaluation items related to quality assessment were used in meta-analysis, with scores ranging from 0 to 40. Based on the STROBE score, the included studies were classified as low quality (0-19), moderate quality (20-29), and high quality (30-40) ([@B10]). If the studies were of low quality, moderate, or high quality, they were considered to be at high, moderate or low risk of bias, respectively. If two authors had contradictory information, a third author (MW) was consulted.

Statistical Analysis
--------------------

Pooled ORs and 95% CIs were evaluated to assess the relationship between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the heterozygous (AT vs. TT), homozygous (AA vs. TT), dominant (AT+AA vs. TT), recessive (AA vs. AT+TT), and allele contrast (A vs. T) models. We conducted stratification analyses by ethnicity, cancer type ("others": one cancer type was investigated in less than 3 studies), study design ("mixed": the source of controls contained both hospital-based and population-based subjects) and risk of bias. The Chi square-based Q-test was used to calculate the heterogeneity among studies. A random-effect model was adopted when *P* \< 0.1 (heterogeneity). Otherwise, a fixed-effect model was adopted ([@B11]). Funnel plots were used to evaluate potential publication bias ([@B12]). All data analyses were performed using R software. All of the P values were two-tailed; *P* \< 0.05 indicated statistical significance.

Results {#s3}
=======

Literature Search
-----------------

As shown in [Figure 1](#F1){ref-type="fig"}, 255 potentially relevant studies were selected from the PubMed, CNKI, EMBASE, WANFANG, and Vip databases. We excluded 86 duplicate articles and 109 publications not investigating the association between the AURKA gene rs2273535 polymorphism and cancer risk after reviewing titles and abstracts. Then, the full texts of the remaining articles were evaluated. One publication ([@B13]) was removed for containing overlapping data. We also excluded 17 publications ([@B14]--[@B30]) because no useful data was reported to calculate ORs and 95% CIs. In addition, we eliminated 3 publications ([@B31]--[@B33]) presenting survival data only. Lastly, we excluded 5 publications ([@B34]--[@B38]) due to deviation from the HWE. Overall, 34 publications with a total of 22,884 cancer cases and 30,497 healthy controls were included in the meta-analysis.

![Flowchart of included publications.](fonc-10-01040-g0001){#F1}

Description and Quality of the Studies
--------------------------------------

The 34 publications actually consisted of 36 case-control studies, because 2 publications included 2 individual studies. The characteristics of these studies were shown in [Supplemental Table 1](#SM1){ref-type="supplementary-material"}. Among these publications, 12 focused on breast cancer ([@B39]--[@B50]), 5 on gastric cancer ([@B51]--[@B55]), 3 on colorectal cancer ([@B56]--[@B58]), 2 on esophageal ([@B59], [@B60]), 2 on liver cancer ([@B61], [@B62]), and 2 on oral cancer ([@B63], [@B64]). Moreover, there was only 1 study for each of the following cancers: lung cancer ([@B65]), neuroblastoma cancer ([@B66]), ovarian cancer ([@B67]), prostate cancer ([@B68]), renal cancer ([@B69]), urinary tract urothelial cancer ([@B70]), uterine cancer ([@B71]), bladder cancer ([@B70]), and endometrial cancer ([@B72]). As evident in [Table 1](#T1){ref-type="table"}, among these case-control studies, 2 of them had low risk of bias, 31 had moderate risk of bias, while 3 had high risk of bias. The shortcomings of low risk of bias research mainly focused on the lack of some descriptions in the results section (describing the numbers of individuals at each stage of the study, reasons for non-participation at each stage and a flow diagram) and methods section (describing comparability of assessment methods, address potential sources of bias, the estimation of the study size). In addition to the shortcomings involved in the low-risk bias study, the moderate-risk bias study also lacked the description in the methods section(explaining how missing data were addressed, how missing data were addressed and how quantitative variables were handled in the analyses), results section(indicating the number of participants with missing data and if relevant, considering translating estimates of relative risk into absolute risk for a meaningful time period) and discussion section (reporting category boundaries when continuous variables were categorized). High-risk bias study not only included the above-mentioned defects, but included the lack of giving the sources and methods of case ascertainment and control selection, the rationale for the choice of cases and controls and matching criteria and the number of controls, clearly defining all outcomes, exposures, predictors, potential confounders, effect modifiers and describing any sensitivity analyses in the methods section. Finally, this meta-analysis contained 19 hospital-based and 15 population-based studies.

###### 

The risk of bias assessment.

  **Name**              **Year**   **STROBE score**   **Risk of bias**
  --------------------- ---------- ------------------ ------------------
  Miao                  2004       22                 Moderate
  Zhiyu Bao             2017       28                 Moderate
  Zheng                 2013       27                 Moderate
  Zhang                 2006       21                 Moderate
  Ying-ChuLin           2017       23                 Moderate
  Ying-ChuLin           2017       23                 Moderate
  Xiaoyan Zhou          2018       24                 Moderate
  Webb                  2006       20                 Moderate
  Vidarsdottir          2007       23                 Moderate
  Tchatchou             2007       21                 Moderate
  Sun                   2004       20                 Moderate
  Shi                   2011       27                 Moderate
  Shan Li               2015       25                 Moderate
  Ruan                  2011       26                 Moderate
  Nicholas J. Taylor    2015       30                 High
  Nicholas J. Taylor    2015       30                 High
  Ming Zhao             2014       14                 Low
  Milam                 2007       22                 Moderate
  Marie-Genica          2010       26                 Moderate
  Lo                    2005       23                 Moderate
  Li-Yuan Zheng         2015       28                 Moderate
  Li Chen               2005       12                 Low
  Jue Tang              2018       23                 Moderate
  Ju                    2006       21                 Moderate
  Hammerschmied         2007       20                 Moderate
  Guenard               2009       21                 Moderate
  Gu                    2007       27                 Moderate
  Feik                  2009       22                 Moderate
  Cox                   2006       23                 Moderate
  Chi-Pin Lee           2015       25                 Moderate
  Chia-Hsuan Chou       2017       16                 Low
  Chen                  2007       20                 Moderate
  Chen                  2009       21                 Moderate
  Bin Wang              2018       25                 Moderate
  Aner Mesic            2016       22                 Moderate
  Andrés López-Cortés   2017       23                 Moderate

Meta-Analysis Results
---------------------

As evident in [Table 2](#T2){ref-type="table"}, [Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, there is significant inter-study heterogeneity under all the genetic models; thus, we used a random-effect model. After calculating crude ORs and 95% CIs, we found that the AURKA gene rs2273535 T\>A polymorphism was associated with increased overall cancer susceptibility (homozygous: OR = 1.17, 95% CI = 1.04-1.33; recessive: OR = 1.15, 95% CI = 1.05-1.25; allele: OR = 1.07, 95% CI = 1.02-1.13). [Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} depicted forest plot of the association between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the dominant and homozygous model. We performed stratification analyses by cancer type, ethnicity, study design and risk of bias. Stratification analysis further indicated that the AURKA gene rs2273535 T\>A polymorphism was associated with increased risk of breast cancer (homozygous: OR = 1.28, 95% CI = 1.12-1.47; recessive: OR = 1.17, 95% CI = 1.05-1.31; allele: OR = 1.09, 95% CI = 1.02-1.17). [Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"} show stratification analysis of the association between the AURKA rs2273535 T\>A polymorphism and cancer risk by cancer type under the dominant and homozygous model. We also checked the association in the Asian population. Interestingly, we only observed significant associations in Asians (recessive: OR = 1.17, 95% CI = 1.05-1.32; allele: OR = 1.09, 95% CI = 1.01-1.18). Moreover, the association remained significant in the subgroups with population-based studies (homozygous: OR = 1.25, 95% CI = 1.07-1.46; recessive: OR = 1.19, 95% CI = 1.07-1.33; allele: OR = 1.10, 95% CI = 1.03-1.19) and moderate risk of bias (homozygous: OR = 1.17, 95% CI = 1.02-1.34; recessive: OR = 1.17, 95% CI = 1.06-1.29; allele: OR = 1.08, 95% CI = 1.02-1.14). [Figure 6](#F6){ref-type="fig"} revealed stratification analysis of the association between the AURKA rs2273535 T\>A polymorphism and cancer risk by risk of bias under the homozygous model.

###### 

The association between the AURKA rs2273535 T\>A polymorphism and cancer risk in the meta-analysis.

  **Variables**      **No. of studies**   **Homozygous**             **Heterozygous**           **Recessive**              **Dominant**               **Allele**         
  ------------------ -------------------- ------------------ ------- ------------------ ------- ------------------ ------- ------------------ ------- ------------------ -------
  All                36                   1.17 (1.04-1.33)   0.000   1.02 (0.97-1.06)   0.096   1.15 (1.05-1.25)   0.000   1.06 (0.99-1.13)   0.003   1.07 (1.02-1.13)   0.000
  **Cancer type**                                                                                                                                                        
  Breast             13                   1.28 (1.12-1.47)   0.089   1.02 (0.96-1.08)   0.098   1.17 (1.05-1.31)   0.008   1.10 (0.99-1.21)   0.042   1.09 (1.02-1.17)   0.006
  Colorectal         3                    1.13 (0.61-2.08)   0.038   1.05 (0.93-1.17)   0.258   1.15 (0.67-1.98)   0.012   1.01 (0.68-1.51)   0.074   1.05 (0.73-1.50)   0.003
  Gastric            5                    0.82 (0.60-1.13)   0.310   0.83 (0.63-1.09)   0.654   0.99 (0.79-1.24)   0.140   0.83 (0.64-1.07)   0.479   0.96 (0.80-1.14)   0.132
  Others             15                   1.15 (0.91-1.45)   0.000   1.02 (0.95-1.10)   0.130   1.14 (0.96-1.36)   0.000   1.05 (0.94-1.17)   0.013   1.08 (0.98-1.18)   0.000
  **Ethnicity**                                                                                                                                                          
  Caucasian          14                   1.15 (0.95-1.39)   0.007   1.02 (0.96-1.08)   0.595   1.11 (0.96-1.28)   0.007   1.04 (0.98-1.10)   0.357   1.05 (0.99-1.11)   0.090
  Asian              20                   1.15 (0.98-1.34)   0.000   1.00 (0.93-1.07)   0.194   1.17 (1.05-1.32)   0.000   1.04 (0.94-1.15)   0.011   1.09 (1.01-1.18)   0.000
  **Strobe score**                                                                                                                                                       
  30-40              2                    1.28 (0.92-1.78)   0.604   1.39 (0.99-1.95)   0.391   0.95 (0.83-1.08)   0.419   1.31 (0.95-1.82)   0.541   1.00 (0.89-1.12)   0.536
  20-29              31                   1.17 (1.02-1.34)   0.000   1.01 (0.95-1.07)   0.097   1.17 (1.06-1.29)   0.000   1.05 (0.97-1.12)   0.002   1.08 (1.02-1.14)   0.000
  0-19               3                    1.18 (0.90-1.53)   0.431   1.07 (0.90-1.28)   0.524   1.15 (0.92-1.45)   0.762   1.10 (0.93-1.30)   0.443   1.09 (0.97-1.23)   0.497
  **Design**                                                                                                                                                             
  HB                 19                   1.10 (0.91-1.33)   0.000   1.01 (0.95-1.08)   0.664   1.10 (0.95-1.27)   0.000   1.02 (0.94-1.11)   0.157   1.05 (0.97-1.13)   0.000
  PB                 16                   1.25 (1.07-1.46)   0.002   1.02 (0.96-1.08)   0.009   1.19 (1.07-1.33)   0.001   1.10 (0.99-1.22)   0.001   1.10 (1.03-1.19)   0.000

*OR, odd ratio; CI, confidence interval; Het, heterogeneity*.

![Forest plot of the association between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the dominant model (AT+AA vs. TT).](fonc-10-01040-g0002){#F2}

![Forest plot of the association between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the homozygous model (AA vs. TT).](fonc-10-01040-g0003){#F3}

![Stratification analysis of the association between the AURKA rs2273535 T\>A polymorphism and cancer risk by cancer type under the dominant model (AT+AA vs. TT).](fonc-10-01040-g0004){#F4}

![Stratification analysis of the association between the AURKA rs2273535 T\>A polymorphism and cancer risk by cancer type under the homozygous model (AA vs. TT).](fonc-10-01040-g0005){#F5}

![Stratification analysis of the association between the AURKA rs2273535 T\>A polymorphism and cancer risk by risk of bias under the homozygous model (AA vs. TT).](fonc-10-01040-g0006){#F6}

Publication Bias
----------------

Symmetry in the funnel plots ([Figures 7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}) suggested that there was no significant publication bias in this meta-analysis (homozygous: P = 0.585; heterozygous: P = 0.939; recessive: P = 0.586; dominant: P = 0.546; allele: P = 0.657).

![Funnel plot of the association between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the dominant model (AT+AA vs. TT).](fonc-10-01040-g0007){#F7}

![Funnel plot of the association between the AURKA rs2273535 T\>A polymorphism and overall cancer risk under the homozygous model (AA vs. TT).](fonc-10-01040-g0008){#F8}

Discussion {#s4}
==========

AURKA is a key factor in regulating thetransition from G2 to M phase during mitosis. The AURKA protein includes a 129-amino acid N-terminal domain that facilitates AURKA nuclear-translocation during mitosis and a 274-amino acid C-terminal kinase catalytic domain ([@B73]). AURKA has been reportedly associated with poor prognosis in medulloblastoma and over-expression in various types of cancer ([@B74]). AURKA protein amplification and over-expression in breast and other tumors is related to centrosomal amplification, dysfunction of cytokinesis, and aneuploidy. Based on genetic mapping studies, AURKA is a potential genetic target for cancer therapy ([@B16]). The AURKA F31I polymorphism (T\>A)(phenylalanine (Phe)\> isoleucine (Ile)) is related to cellular transformation and distinctly enhances chromosomal instability ([@B75]). This polymorphism can also cause an obstruction in p53 binding and decreased degradation of AURKA by changing the activity of the AURKA box 1 ([@B16]). Research has shown that the stabilized over-expression of AURKA results in centrosomal amplification, abnormal cytokinesis, chromosomal instability, and the promotion of tumorigenesis. Numerous studies have been performed to explore the association between the rs2273535 polymorphism and the risk of various types of cancer. López-Cortés et al. ([@B50]) carried out a study in 2018 to investigate the role of single nucleotide polymorphism AURKA T91A (rs2273535) in a high altitude Ecuadorian Mestizo population consisting of 100 patients and 100 controls, and found a significant relationship between the rs2273535 genotype and a higher risk of breast cancer development. This association was confirmed in different types of cancer, including hepatocellular carcinoma (HCC) by Bao et al. ([@B62]) with 788 cases and 815 controls, urinary tract urothelial cancer by Lin et al. ([@B70]) with 185 cases and 188 controls, gastric cancer by Zhou et al. ([@B51]) with 381 cases and 468 controls, as well as other types of cancer. However, opposing results were also frequently reported. A case-control study containing 501 prostate cancer and 427 control subjects conducted by Feik et al. ([@B68]) revealed that the AURKA rs2273535 polymorphism was not found to be related to prostate cancer risk. Additionally, Ju et al. ([@B54]) reported that this polymorphism was not related to gastric cancer susceptibility, by studying 501 cases and 427 controls. Tang et al. ([@B66]) selected 393 cases and 812 controls, and the results indicated that none of the AURKA polymorphisms were associated with neuroblastoma susceptibility in two distinct Chinese populations. Several meta-analyses have also been conducted, and unfortunately the results were still inconclusive ([@B76]--[@B80]). In this meta-analysis, the association between the AURKA gene rs2273535 T\>A polymorphism and cancer risk based on 36 eligible case-control studies, with a total of 22,884 cancer cases and 30,497 healthy controls, was estimated. Among these case-control studies, 2 of them had low risk of bias, 31 had moderate risk of bias, while 3 had high risk of bias. Most quality scores of the included studies were higher than 20 (low to moderate risk of bias). Overall, our results indicated that this polymorphism might increase the overall risk of cancer, especially breast cancer.

However, there were some limitations in this meta-analysis. First, only publications written in Chinese or English were selected. Second, the number of studies for certain cancer types was inadequate, such as colorectal cancer (\<5 studies). There were 3 included studies having high risk of bias (0 ≤ STROBE score ≤ 19); further studies with low risk of bias are needed to validate the true association. In addition, other factors may also influence cancer risk, such as age and living habits. Our findings might suffer from potential confounding bias due to the lack of original data. Taken together, the results should be interpreted with caution.

To conclude, this meta-analysis suggests that the AURKA gene rs2273535 T\>A polymorphism is significantly associated with an overall increased cancer risk, especially breast cancer. In the research, most of the included studies had low to moderate risk of bias. Future well-designed, large-scale studies that report upon the association of the rs2273535 polymorphism and cancer, in multiple cancer types, are required to validate the findings of this study.
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